Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 15.71M | 15.71M | 16.65M | 16.23M | 13.81M | 12.92M |
Gross Profit | -8.52M | 14.42M | 15.36M | -2.60M | -4.31M | -2.32M |
EBITDA | -11.04M | -11.08M | -13.42M | -10.78M | -8.02M | -3.06M |
Net Income | -26.16M | -26.16M | -37.45M | -18.07M | -12.43M | -9.35M |
Balance Sheet | ||||||
Total Assets | 124.71M | 124.71M | 138.76M | 159.52M | 174.36M | 172.08M |
Cash, Cash Equivalents and Short-Term Investments | 2.84M | 2.84M | 3.16M | 11.05M | 15.84M | 10.29M |
Total Debt | 58.21M | 58.21M | 46.10M | 80.77M | 87.30M | 92.26M |
Total Liabilities | 69.07M | 69.07M | 57.01M | 114.60M | 120.31M | 112.90M |
Stockholders Equity | 55.64M | 55.64M | 81.74M | 44.93M | 54.05M | 59.18M |
Cash Flow | ||||||
Free Cash Flow | -11.08M | -10.78M | -14.80M | -19.89M | -11.26M | -9.72M |
Operating Cash Flow | -10.93M | -10.63M | -14.26M | -5.45M | -7.15M | -4.26M |
Investing Cash Flow | 112.97K | 113.13K | -263.72K | -1.45M | 3.72M | -5.25M |
Financing Cash Flow | 10.50M | 10.20M | 6.64M | 2.11M | 9.18M | 10.66M |
The Singapore Institute of Advanced Medicine Holdings Ltd. has dissolved its Strategic Review Committee (SRC) as of August 8, 2025. The Board of Directors will now directly handle the functions and recommendations previously managed by the SRC to streamline decision-making and expedite the implementation of initiatives.